➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Boehringer Ingelheim
Medtronic
Moodys
Johnson and Johnson

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 8,410,045

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,410,045
Title:Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
Abstract: The present invention relates to a novel compound of use in the improved delivery of therapeutic drug agents into target cells or tissues, composition comprising the same and uses thereof. The compound is more specifically a conjugate of a peptide moiety and a camptothecin, a derivative or analog thereof which provides numerous benefits, including enhancement in terms of aqueous solubility, pharmacokinetics and tissue distribution, enlargement of the therapeutic index, and limitation of the inter-patient metabolic variability, as well as improvement of delivery of the biologically active ingredient to the target cells or tissues.
Inventor(s): Michel; Matthieu (Le Vesinet, FR), Ravel; Denis (Paris, FR), Ribes; Fabien (Marseille, FR), Tranchant; Isabelle (Le Kremlin-Bic tre, FR)
Assignee: Drais Pharmaceuticals, Inc. (Bridgewater, NJ)
Application Number:12/295,508
Patent Claims:see list of patent claims

Details for Patent 8,410,045

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   Start Trial Drais Pharmaceuticals, Inc. (Bridgewater, NJ) 2026-03-30 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Drais Pharmaceuticals, Inc. (Bridgewater, NJ) 2026-03-30 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Drais Pharmaceuticals, Inc. (Bridgewater, NJ) 2026-03-30 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial Drais Pharmaceuticals, Inc. (Bridgewater, NJ) 2026-03-30 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial Drais Pharmaceuticals, Inc. (Bridgewater, NJ) 2026-03-30 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Drais Pharmaceuticals, Inc. (Bridgewater, NJ) 2026-03-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Medtronic
AstraZeneca
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.